These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23558901)

  • 21. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies.
    Kim H; Rafiuddin-Shah M; Tu HC; Jeffers JR; Zambetti GP; Hsieh JJ; Cheng EH
    Nat Cell Biol; 2006 Dec; 8(12):1348-58. PubMed ID: 17115033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J; Huang K; O'Neill KL; Pang X; Luo X
    Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of pro- and antiapoptotic molecules of the Bcl-2 family in human islets postisolation.
    Campbell PD; Weinberg A; Chee J; Mariana L; Ayala R; Hawthorne WJ; O'Connell PJ; Loudovaris T; Cowley MJ; Kay TW; Grey ST; Thomas HE
    Cell Transplant; 2012; 21(1):49-60. PubMed ID: 21535910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationship between BH3 mimetic S1 and expression of BCL-2 family members in acute myeloid leukemia].
    Wang XB; Shi M; Mu LJ; Sun J; Li WP; Xue ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):39-44. PubMed ID: 25687043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BH3 domains other than Bim and Bid can directly activate Bax/Bak.
    Du H; Wolf J; Schafer B; Moldoveanu T; Chipuk JE; Kuwana T
    J Biol Chem; 2011 Jan; 286(1):491-501. PubMed ID: 21041309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p14(ARF)-induced apoptosis in p53 protein-deficient cells is mediated by BH3-only protein-independent derepression of Bak protein through down-regulation of Mcl-1 and Bcl-xL proteins.
    Müer A; Overkamp T; Gillissen B; Richter A; Pretzsch T; Milojkovic A; Dörken B; Daniel PT; Hemmati P
    J Biol Chem; 2012 May; 287(21):17343-17352. PubMed ID: 22354970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues.
    Droga-Mazovec G; Bojic L; Petelin A; Ivanova S; Romih R; Repnik U; Salvesen GS; Stoka V; Turk V; Turk B
    J Biol Chem; 2008 Jul; 283(27):19140-50. PubMed ID: 18469004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis.
    Song T; Yu X; Liu Y; Li X; Chai G; Zhang Z
    Chembiochem; 2015 Mar; 16(5):757-65. PubMed ID: 25711460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Bcl-2 homology domain 3 (BH3)-only proteins Bim and bid are functionally active and restrained by anti-apoptotic Bcl-2 family proteins in healthy liver.
    Kodama T; Hikita H; Kawaguchi T; Saito Y; Tanaka S; Shigekawa M; Shimizu S; Li W; Miyagi T; Kanto T; Hiramatsu N; Tatsumi T; Takehara T
    J Biol Chem; 2013 Oct; 288(42):30009-30018. PubMed ID: 23986435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
    Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.